27 January 2021
tranScrip is delighted to announce a significant minority investment from Palatine Private Equity Impact Fund, which complements the existing investment of tranScrip’s own Partners. The deal is a landmark for tranScrip, underpinning its growth as a leading specialist service provider.
ProductLife Group already has a fairly long success story: born in 1993, focusing on RA since 2006 and after becoming a Group, through acquisitions from 2012 onwards, PLG was reborn once again after LBO by 21Invest.
All along, it has kept the ProductLife vision of contributing to improve human health, with its main competences, regulatory affairs, safety & vigilances and quality compliance.
In 2020, ProductLife Group has reached a first step of notoriety as PLG, a European leading service provider for top pharmaceutical companies.
Saffron Walden, UK, 21st January 2021 / Domainex Ltd., a leading provider of integrated drug discovery services, is pleased to welcome David Cronk, CBiol, MRSB, to the team as its new Chief of Staff. The Company has also promoted long standing team member and previous Head of Chemistry, Dr Ray Boffey, to Executive Director of Medicines Research. Following a successful period of growth and expansion of its research team, both David and Ray bring a wealth of drug discovery experience and will further support Domainex’s ongoing growth plans.
The cfPure® Cell Free DNA Extraction Kit from AMSBIO is a magnetic bead-based DNA extraction kit designed to isolate circulating cell free DNA (cfDNA) from human plasma or serum samples.
Research Triangle Park, NC, USA and Cambridge, UK, 20 January 2021 – Inivata, a leader in liquid biopsy, today announces that the first patients have been tested using InVisionFirst®-Lung as part of the Phase II ALKALINE trial sponsored by the European Organisation for Research and Treatment of Cancer (EORTC). As part of the study Inivata’s InVisionFirst-Lung liquid biopsy will be used to test and monitor ALK positive non-small cell lung cancer (NSCLC) patients initiating treatment with lorlatinib, Pfizer Inc.’s third generation ALK inhibitor therapy.
Cambridge and London, UK, 18 January 2021:
Metrion Biosciences Limited (Metrion), the specialist ion channel CRO and drug discovery company, and LifeArc, a leading UK independent medical research charity, today announced a 12-month extension of their neuroscience drug discovery collaboration, as a result of the continued success of their ongoing agreement.
Cambridge, United Kingdom – 14 January 2021 - Congenica, the digital health company enabling rapid and accurate analysis of complex genomic data to transform people’s lives, today announces the launch of a Patient Advocacy and Engagement Advisory Board.
Taiho Pharmaceutical Co, Ltd., (hereinafter Taiho) announces that it and Astex Pharmaceuticals (UK), (hereinafter Astex), both Otsuka group companies, have granted an exclusive license under their joint, small-molecule drug discovery program targeting SHP2 to Merck & Co., Inc., Kenilworth, NJ, USA, known as MSD outside the United States and Canada (hereinafter MSD) through a subsidiary.
Cambridge, UK, 13 January 2021: Today Abcam (AIM:ABC; NASDAQ:ABCM), a global innovator in life science reagents and tools, was honored with a Employees’ Choice Award recognizing the Best Places to Work in 2021 by Glassdoor, the worldwide leader on insights about jobs and companies.